(doi:10.1001/jama.2015.16669; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: The study was funded by Novocure Ltd. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.
Ad Statistics
Times Displayed: 21862
Times Visited: 433 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Editorial: Alternating Electric Fields for the Treatment of Glioblastoma
The mechanisms whereby the novel approach used in this study can treat tumors and leverage chemotherapy remain unclear, writes John H. Sampson, M.D., Ph.D., M.H.Sc., M.B.A., of Duke University, Durham, N.C.
"Given the survival benefit reported in this study, it should now be a priority to understand the scientific basis for the efficacy of TTFields; achieving this may require the development of robust and widely available large animal models for glioblastoma, which do not currently exist. Perhaps most concerning, because of the study design chosen, doubts may remain as to the true efficacy of this therapy. So, if TTFields therapy fails to be adopted, will this decision be attributed to professional parochialism or to data that are not trusted? The current study provides additional important data on a novel device for the treatment of glioblastoma, but it will not completely resolve that debate."
(doi:10.1001/jama.2015.16701; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: Please see the article for additional information, including financial disclosures, funding and support, etc.
Back to HCB News
